mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment

Publisher： John Wiley & Sons Inc

E-ISSN： 1750-3639|25|6|755-759

ISSN： 1015-6305

Source： BRAIN PATHOLOGY, Vol.25, Iss.6, 2015-11, pp. : 755-759

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

mTORC1 et sirolimus

By Tartarin Pauline   Froment Pascal  

Médecine/sciences, Vol. 29, Iss. 2, 2013-02 ,pp. : 200-205

Edp Sciences

Access to resources Recommend Favorite

A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3481-3490

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTORC1 and the regulation of skeletal muscle anabolism and mass

By Adegoke Olasunkanmi A.J.   Abdullahi Abdikarim   Tavajohi-Fini Pegah  

Applied Physiology, Nutrition, and Metabolism, Vol. 37, Iss. 3, 2012-06 ,pp. : 395-406

NRC Research Press

Access to resources Recommend Favorite

O‐18: mTORC1 is a novel HCV host factor

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 11-11

John Wiley & Sons Inc

Access to resources Recommend Favorite

Coactivation d’AMPK et de mTORC1

By Tamburini Jérôme   Poulain Laury   Bouscary Didier   Sujobert Pierre  

Médecine/sciences, Vol. 31, Iss. 10, 2015-10 ,pp. : 836-839

Edp Sciences

Access to resources Recommend Favorite